TY - JOUR
T1 - The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase
T2 - A potent target for cardiovascular diseases
AU - Kawase, Yoshiaki
AU - Hajjar, Roger J.
PY - 2008
Y1 - 2008
N2 - The cardiac isoform of the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2a) is a calcium ion (Ca2+) pump powered by ATP hydrolysis. SERCA2a transfers Ca2+ from the cytosol of the cardiomyocyte to the lumen of the sarcoplasmic reticulum during muscle relaxation. As such, this transporter has a key role in cardiomyocyte Ca2+ regulation. In both experimental models and human heart failure, SERCA2a expression is significantly decreased, which leads to abnormal Ca2+ handling and a deficient contractile state. Following a long line of investigations in isolated cardiac myocytes and small and large animal models, a clinical trial is underway that is restoring SERCA2a expression in patients with heart failure by use of adeno-associated virus type 1. Beyond its role in contractile abnormalities in heart failure, SERCA2a overexpression has beneficial effects in a host of other cardiovascular diseases. Here we describe the mechanism of Ca2+ regulation by SERCA2a, examine the beneficial effects as well as the failures, risks and complexities associated with SERCA2a overexpression, and discuss the potential of SERCA2a as a target for the treatment of cardiovascular disease.
AB - The cardiac isoform of the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2a) is a calcium ion (Ca2+) pump powered by ATP hydrolysis. SERCA2a transfers Ca2+ from the cytosol of the cardiomyocyte to the lumen of the sarcoplasmic reticulum during muscle relaxation. As such, this transporter has a key role in cardiomyocyte Ca2+ regulation. In both experimental models and human heart failure, SERCA2a expression is significantly decreased, which leads to abnormal Ca2+ handling and a deficient contractile state. Following a long line of investigations in isolated cardiac myocytes and small and large animal models, a clinical trial is underway that is restoring SERCA2a expression in patients with heart failure by use of adeno-associated virus type 1. Beyond its role in contractile abnormalities in heart failure, SERCA2a overexpression has beneficial effects in a host of other cardiovascular diseases. Here we describe the mechanism of Ca2+ regulation by SERCA2a, examine the beneficial effects as well as the failures, risks and complexities associated with SERCA2a overexpression, and discuss the potential of SERCA2a as a target for the treatment of cardiovascular disease.
UR - http://www.scopus.com/inward/record.url?scp=50649097202&partnerID=8YFLogxK
U2 - 10.1038/ncpcardio1301
DO - 10.1038/ncpcardio1301
M3 - Review article
C2 - 18665137
AN - SCOPUS:50649097202
VL - 5
SP - 554
EP - 565
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
SN - 1759-5002
IS - 9
ER -